News

The experimental therapy barzolvolimab can reduce disease activity in people with chronic spontaneous urticaria (CSU) — an inflammatory disorder characterized by recurrent itching and hives — who experience angioedema, according to results from two Phase 3 clinical trials. Celldex Therapeutics, the company developing barzolvolimab, plans to use the…

Dawnzera (donidalorsen), a preventive therapy used to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), has been approved in Canada for adults and adolescents ages 12 and older. The decision by Health Canada follows Dawnzera’s approval for the same indication in the U.S. last…

Hereditary angioedema (HAE) should be considered in children with recurrent severe abdominal pain and vomiting, especially when such episodes are separated by complete recovery or accompanied by unexplained swelling. That’s the recommendation of a team of researchers in Argentina, who treated a young boy with recurring severe pain who…

New trial data show that BW-20805, Argo Biopharma‘s long-acting injection therapy for hereditary angioedema (HAE), continues to substantially reduce swelling attacks among adults with HAE for as long as six months after treatment. These findings come from a larger group of people with HAE taking part in the…

Lower blood levels of an enzyme involved in processes such as tissue remodeling and wound healing may help distinguish people with idiopathic angioedema, a form of angioedema that has no obvious cause, from those with hereditary angioedema (HAE) or mast cell-mediated angioedema, a small study in China suggested. Levels…

Once-daily treatment with deucrictibant extended-release (XR) tablets reduced the frequency of swelling attacks among people with hereditary angioedema (HAE) by more than 80% compared with a placebo in a late-stage clinical trial. Moreover, lasting benefits were seen for study participants with different types of the chronic genetic disease.

A woman in her early 20s with systemic lupus erythematosus (SLE), the most common form of the autoimmune disease lupus, developed recurrent episodes of angioedema despite having normal C1 esterase inhibitor (C1-INH) levels and function, according to a case report. Instead, blood tests showed signs that the complement…

The U.S. Food and Drug Administration (FDA) is slated to decide by early next year whether or not to approve a one-time gene-editing therapy to potentially control swelling in hereditary angioedema (HAE). The regulatory agency accepted an application from Intellia Therapeutics seeking approval of its infusion therapy…

Takhzyro (lanadelumab) is a safe and effective long-term preventive treatment that can reduce the frequency of hereditary angioedema (HAE) attacks and improve disease control and quality of life, according to a review of clinical and real-world data. The review, “Lanadelumab Use for Hereditary Angioedema Long-Term…

Biocryst Pharmaceuticals‘ once-daily oral therapy Orladeyo (berotralstat) is now approved in Japan to prevent swelling attacks in children with hereditary angioedema (HAE) as young as 2 years old. Japan’s Ministry of Health, Labor and Welfare (MHLW) first approved Orladeyo in 2021 as a treatment for HAE…